Enpro (NPO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
18 Feb, 2026Strategic evolution and value creation
Transitioned from resolving legacy liabilities (2002–2018) to portfolio optimization (2019–2024) and now focuses on accelerating profitable growth as a premium industrial technology compounder (2025+).
Achieved over $1B from 13 divestitures and invested $1.7B in five acquisitions, shifting to high-margin, technology-driven markets.
Current strategy targets mid- to high single-digit organic growth and EBITDA margins above 25%.
Financial performance and outlook
2025 revenue reached $1.1B with adjusted EBITDA of $278M (24.3% margin) and a market cap of $5.7B as of February 2026.
2026 guidance projects 8–12% revenue growth, adjusted EBITDA of $305–$320M, and adjusted diluted EPS of $8.50–$9.20.
Free cash flow rose 18% to $153.1M in 2025; capex was $48.1M, with two-thirds for growth and efficiency.
Net leverage stands at approximately 2.0x trailing 12-month adjusted EBITDA, with $580M available under a $800M revolver.
Dividend increased for the 11th consecutive year, with $26.2M paid in 2025 and a 0.5% yield.
Segment highlights and acquisitions
Sealing Technologies segment (Garlock, STEMCO, Technetics) delivered 2025 sales of $732M and a 32.8% adjusted EBITDA margin, with strong aftermarket presence.
Advanced Surface Technologies segment posted $412M in 2025 sales and a 20.1% adjusted EBITDA margin, focusing on semiconductor and high-growth markets.
Recent acquisitions: Overlook Industries (biopharma single-use technologies) and Alpha Measurement Solutions (liquid analytical sensors), both integrated into Sealing Technologies.
Latest events from Enpro
- Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPO
Q2 20242 Feb 2026 - Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPO
Q3 202416 Jan 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPO
Q4 202423 Dec 2025 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPO
Proxy Filing1 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025 - Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPO
Proxy Filing1 Dec 2025